CLBS - カラドリアス・バイオサイエンス （Caladrius Biosciences Inc.） カラドリアス・バイオサイエンスCLBSのチャート
CLBSの企業情報
| symbol | CLBS |
|---|---|
| 会社名 | Caladrius Biosciences Inc （カラドリアス・バイオサイエンス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Hospital/Nursing Management |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Caladrius Biosciences Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company''s lead product candidate CLBS03 is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient''s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study a Phase II prospective randomized placebo-controlled double-blind clinical trial to evaluate its Treg product candidate CLBS03 in adolescents with recent onset T1D. The Company plans to develop its product candidate CLBS12 in Japan which is an autologous therapy that derives its cells from peripheral blood through apheresis. カラドリアス・バイオサイエンスは米国のバイオテクノロジ―企業。独自の細胞治療製品の開発に従事し、再生医療分野でのサ―ビスを提供する。虚血に対処するための治療法の開発、急性心筋梗塞後の損傷した心筋を治療、免疫系の不均衡によって引き起こされる疾患を治療、テクノロジ―再生医療プラットフォ―ムなどがある。 Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”). |
| 本社所在地 | 106 Allen Road Fourth Floor Basking Ridge NJ 07920 USA |
| 代表者氏名 | David J. Mazzo デビットJ.マッツォ |
| 代表者役職名 | Chief Executive Officer Independent Director |
| 電話番号 | +1 908-842-0100 |
| 設立年月日 | 29465 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 221人 |
| url | https://www.caladrius.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/clbs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -22.53046 |
| 終値（lastsale） | 5.01 |
| 時価総額（marketcap） | 48724464.42 |
| 時価総額 | 時価総額（百万ドル） 44.34802 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -5.95137 |
| 当期純利益 | 当期純利益（百万ドル） 13.58047 |
| 決算概要 | 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Caladrius Biosciences Inc revenues was not reported. Net loss before extraordinary items increased 5% to $9.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.95. |
CLBSのテクニカル分析
CLBSのニュース
Peripheral Artery Disease Market to Showcase Growth at a Paltry CAGR of 4% During the Study Period (2019-2032) | DelveInsight 2023/03/29 15:30:00 Kwhen Finance
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics 2022/09/15 13:15:00 GlobeNewswire
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”
Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022 2022/09/08 12:00:00 GlobeNewswire
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events:
Caladrius Biosciences'' Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer 2022/08/10 12:00:00 Benzinga
Study to be part of Roche''s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius'' initial investment in Cend BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS ) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend"), today announced Cend''s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. ("Roche") to evaluate Cend''s lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq ® ), Roche''s PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"). Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study. "We are extremely pleased to work with Roche, a global leader in oncology, to explore the potential of CEND-1 in combination with chemotherapy and immunotherapy for the treatment of pancreatic cancer," stated David Slack, Chief Executive Officer of Cend. "We are committed to exploring applications of CEND-1 to improve clinical outcomes for patients with this deadly disease.
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics 2022/09/15 13:15:00 GlobeNewswire
Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”
Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022 2022/09/08 12:00:00 GlobeNewswire
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will participate in the following investor events:
Caladrius Biosciences'' Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer 2022/08/10 12:00:00 Benzinga
Study to be part of Roche''s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius'' initial investment in Cend BASKING RIDGE, N.J. and SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS ) ("Caladrius" or the "Company") and Cend Therapeutics, Inc. ("Cend"), today announced Cend''s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd. ("Roche") to evaluate Cend''s lead investigational drug, CEND-1, in combination with atezolizumab (Tecentriq ® ), Roche''s PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"). Under the terms of the agreement, Roche will be responsible for operational management of the trial while Cend and Roche share equally in the costs of the CEND-1 treatment arms in the study. "We are extremely pleased to work with Roche, a global leader in oncology, to explore the potential of CEND-1 in combination with chemotherapy and immunotherapy for the treatment of pancreatic cancer," stated David Slack, Chief Executive Officer of Cend. "We are committed to exploring applications of CEND-1 to improve clinical outcomes for patients with this deadly disease.
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript 2022/08/05 02:59:06 Seeking Alpha
Caladrius Biosciences, Inc. (NASDAQ:NASDAQ:CLBS) Q2 2022 Results Conference Call August 04, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David…
Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology 2022/07/06 12:00:00 GlobeNewswire
Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacy Peer-reviewed study data suggest CEND-1, in combination with gemcitabine and nab-paclitaxel, demonstrates favorable safety and tolerability along with encouraging efficacy
Caladrius Biosciences to Present at the BIO International Convention 2022 2022/06/08 12:00:00 GlobeNewswire
BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.
Investment - Zacks: Brokerages Expect Caladrius Biosciences, Inc. to Announce -$0.10 Earnings Per Share 2022/06/05 05:09:10 Business Mag
Equities research analysts expect Caladrius Biosciences, Inc. to report earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have…
The Daily Biotech Pulse: INmune Bio''s Planned Alzheimer''s Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures 2022/05/24 12:24:46 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus INmune Bio Planned Midstage Alzheimer''s Trial Put On FDA Hold The FDA has requested additional information on the Chemistry Manufacturing and Controls of the newly manufactured INmune Bio Inc''s (NASDAQ: INMB ) XPro1595. As part of the communication, the FDA placed the company''s Investigational New Drug application for the Phase 2 trial of XPro in Alzheimer''s Disease on clinical hold. INmune plans to provide additional updates pending discussion with the FDA. The Phase 2 trial of XPro remains open in Australia and continues to enroll patients. Shares are down 27.2% at $5.29 during the premarket session. Caladrius Biosciences Stops Enrollment In Midstage Heart Disease Study Caladrius Biosciences Inc (NASDAQ: CLBS ) suspended patient enrollment in its Phase 2b FREEDOM Trial of Xowna for coronary microvascular dysfunction. The FREEDOM trial enrolled approximately one-third of the targeted 105 patients, and at this rate, more than four years would likely be required to reach the primary endpoint follow-up at six months post-treatment for all subjects.
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference 2022/05/18 12:00:00 GlobeNewswire
BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.